Global Search | Novartis

Hide Filters

Showing 2804 results

Statement / Aug 11, 2022

Zolgensma acute liver failure update
Media Library / Aug 11, 2022

Gene Therapy Manufacturing in North Carolina
Media Library / Aug 11, 2022

Spinal Muscular Atrophy
Media Library / Aug 11, 2022

About Gene Therapy
Media Library / Aug 11, 2022

Screen the Unseen: Newborn Screening for SMA
Statement / Jun 01, 2022

Novartis resumes business in Ukraine

Novartis condemns the war in Ukraine and has been providing humanitarian support, financial donations as well as considerable volumes of medicines to those people impacted by the war.
Featured News / Sep 17, 2020

Novartis at ESMO

Latest oncology resources and news surrounding Novartis data featured at European Society for Medical Oncology (ESMO)
Featured News / Feb 08, 2022

Novartis Co-Creating Impact Summit 2021

Over 1,800 delegates came together at the annual Co-Creating Impact Summit to explore how understanding ‘impact’ is a crucial step in ensuring business makes a positive contribution to the world.
Press release / Jun 27, 2022

New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)

New data from the Phase 3 ASCLEPIOS I/II trials and ALITHIOS open-label extension show that after four years nearly 8 out of 10 of people with relapsing multiple sclerosis (RMS) treated continuously…
Press release / Mar 02, 2022

Novartis peer-reviewed safety and tolerability data further strengthens Kesimpta’s (ofatumumab) favorable benefit-risk profile in patients with relapsing multiple sclerosis

Multiple Sclerosis Journal has published data from the ALITHIOS open-label extension study which provide a robust picture of the continuous safety data for Kesimpta, showing it was well tolerated in…